Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM | PTCy versus ATG as haploidentical transplant prophylaxis

Arnon Nagler • 21 Oct 2021
COSTEM
Anti-thymocyte globulin Cyclophosphamide

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, shares his views on whether post-transplant cyclophosphamide (PTCy) is superior to anti-thymocyte globulin (ATG) as prophylaxis in haploidentical transplant. Prof. Nagler outlines the mechanism of action of PTCy, reporting that it reduces transplanted-related mortality, but comments that further studies are needed to compare it’s efficacy to that of ATG. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals